Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer.
about
Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients.Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapyNucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.In vitro analysis of transport and metabolism of 4'-thiothymidine in human tumor cells.Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.Levels of human equilibrative nucleoside transporter-1 are higher in proliferating regions of A549 tumor cells grown as tumor xenografts in vivo.Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence.The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma PatientsMolecular predictors of gemcitabine response in pancreatic cancer.Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.
P2860
Q34234101-0D65820A-41B5-4E9C-83F6-77AD5274BA82Q34283650-02E97320-79DE-48FF-9A70-905A533CE42CQ35066350-F8DFB23C-13E3-4D7D-A901-F5B674EEF4B4Q35286787-BB89A04B-0654-4295-A3B9-B9DC9E8D2C25Q36210934-93FC30B0-8974-46A2-A65F-9AD354ED190EQ36338979-22B34E17-B6FD-4C85-8B1E-6FE1B5DB6238Q36342657-0BC50AF9-8552-4327-B61A-369EC133AE22Q36351914-7BAB2289-57BF-49DE-852E-52B6434E052BQ36374851-5814D92A-3F52-4AB7-BCF6-506F5A4AC419Q36762499-83419CF8-F43C-4646-8C11-56C1F94C7297Q36884377-9E7A18C0-1F17-47AE-BBF2-F4A2E140751AQ39250668-A303026A-8D78-451E-B836-8E280FCC0DB7Q50569337-3E3EFDD5-199D-4112-A691-916CE9DB7953
P2860
Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Prognostic role of human equil ...... with resected gastric cancer.
@en
Prognostic role of human equilibrative transporter 1
@nl
type
label
Prognostic role of human equil ...... with resected gastric cancer.
@en
Prognostic role of human equilibrative transporter 1
@nl
prefLabel
Prognostic role of human equil ...... with resected gastric cancer.
@en
Prognostic role of human equilibrative transporter 1
@nl
P2093
P2860
P50
P356
P1476
Prognostic role of human equil ...... s with resected gastric cancer
@en
P2093
Andrea Onetti Muda
Antonio Russo
Carol Cass
Chiara Spoto
Francesco Graziano
Maria Elisabetta Fratto
Pier Adelchi Ruffini
Pietro Muretto
Raymond Lai
Sergio Rizzo
P2860
P304
P356
10.1002/JCP.22045
P577
2010-05-01T00:00:00Z